Skip to main content
Top

20-11-2023 | Commentary

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

Authors: Giovany Orozco-Leal, Eugenie Evelynne Johnson, Sedighe Hosseinijebeli, Tomos Robinson, Tara Homer, Claire H. Eastaugh, Catherine Richmond, Louise Tanner, Nick Meader, Ryan Kenny, Sheila A. Wallace, Stephen Rice

Published in: PharmacoEconomics

Login to get access

Excerpt

Health economic decision models of cancers usually model lifetime survival to estimate the cost effectiveness of a new surgical or drug intervention for cancer. This requires the extrapolation of survival data beyond the trial follow-up period [ 1]. Where the primary outcome of a trial is progression-free survival or objective response, then overall survival data in a company submission (CS) to the National Institute of Health and Care Excellence (NICE) are especially immature. Short follow-up periods pose an extrapolation challenge when hazard rates and treatment effect may vary over time. Where it is believed that a healthcare technology is able to cure some patients, there are additional challenges in modelling long-term survival [ 2]. …
Literature
2.
go back to reference Rutherford M, Lambert P, Sweeting M, Pennington R, Crowther M, Abrams K, Latimer N. NICE DSU technical support document 21: flexible methods for survival analysis [TSD21]: Decision Support Unit, ScHARR, University of Sheffield; 2020. http://​www.​nicedsu.​org.​uk. Rutherford M, Lambert P, Sweeting M, Pennington R, Crowther M, Abrams K, Latimer N. NICE DSU technical support document 21: flexible methods for survival analysis [TSD21]: Decision Support Unit, ScHARR, University of Sheffield; 2020. http://​www.​nicedsu.​org.​uk.
4.
go back to reference Bristol Myers Squibb Pharmaceuticals Ltd. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer [ID3757]. Document B. Company evidence submission—original submission received on 23 September 2022. Bristol Myers Squibb Pharmaceuticals; 2022. Bristol Myers Squibb Pharmaceuticals Ltd. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer [ID3757]. Document B. Company evidence submission—original submission received on 23 September 2022. Bristol Myers Squibb Pharmaceuticals; 2022.
13.
go back to reference Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. CrossRefPubMedPubMedCentral Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. CrossRefPubMedPubMedCentral
15.
go back to reference National Institute for Health and Care Excellence (NICE). Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [TA761]. London: National Institute for Health and Care Excellence (NICE); 19 Jan 2022. https://​www.​nice.​org.​uk/​guidance/​ta761. National Institute for Health and Care Excellence (NICE). Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [TA761]. London: National Institute for Health and Care Excellence (NICE); 19 Jan 2022. https://​www.​nice.​org.​uk/​guidance/​ta761.
Metadata
Title
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
Authors
Giovany Orozco-Leal
Eugenie Evelynne Johnson
Sedighe Hosseinijebeli
Tomos Robinson
Tara Homer
Claire H. Eastaugh
Catherine Richmond
Louise Tanner
Nick Meader
Ryan Kenny
Sheila A. Wallace
Stephen Rice
Publication date
20-11-2023
Publisher
Springer International Publishing
Published in
PharmacoEconomics
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-023-01328-w